United States-based Eli Lilly and Company has agreed to acquire Loxo Oncology, a Connecticut-based biopharmaceutical company that develops cancer drugs, it was reported yesterday.
The deal is valued at USD8bn in cash. Under the terms of the contract, Lilly will acquire all of the Loxo Oncology shares at USD235 per share. The transaction is likely to be completed by the end of the first quarter of 2019, depending on meeting of customary closing conditions such as receipt of regulatory approvals and approval of Loxo Oncology's shareholders.
Lilly Oncology president Anne White said, 'The acquisition of Loxo Oncology represents an exciting and immediate opportunity to expand the breadth of our portfolio into precision medicines and target cancers that are caused by specific gene abnormalities.'
Loxo Oncology chief operating officer Jacob Van Naarden said, 'We are excited to have reached this agreement with a team that shares our commitment to ensuring that emerging translational science reaches patients in need. We are confident that the work we have started, which includes an FDA approved drug, and a pipeline spanning from Phase two to discovery, will continue to thrive in Lilly's hands.'
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial